The DOI matches its Crossref record; 402 of the 402 references it cites were found in a registry or an index.
Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs
Open accessAbstract
Nucleoside, nucleotide, and base analogs have been in the clinic for decades to treat both viral pathogens and neoplasms. More than 20% of patients on anticancer chemotherapy have been treated with one or more of these analogs. This review focuses on the chemical synthesis and biology of anticancer nucleoside, nucleotide, and base analogs that are FDA-approved and in clinical development since 2000. We highlight the cellular biology and clinical biology of analogs, drug resistance mechanisms, and compound specificity towards different cancer types. Furthermore, we explore analog syntheses as well as improved and scale-up syntheses. We conclude with a discussion on what might lie ahead for medicinal chemists, biologists, and physicians as they try to improve analog efficacy through prodrug strategies and drug combinations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–400 of 402
Rogstad, D. K., Herring, J. L., Theruvathu, J. A., Burdzy, A., Perry, C. C., Neidigh, J. W., & Sowers, L. C. (2009) · Chemical Research in Toxicology · doi:10.1021/tx900131u · Cited by 94
Anglin, J. L., Deng, L., Yao, Y., Cai, G.-B., Liu, Z., Jiang, H., Cheng, G., Chen, P., Dong, S., & Song, Y. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300917h · Cited by 94
Older and new purine nucleoside analogs for patients with acute leukemias
Robak, P. J., & Robak, T. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.03.006 · Cited by 94
Two Distinct Molecular Mechanisms Underlying Cytarabine Resistance in Human Leukemic Cells
Cai, J., Damaraju, V. L., Groulx, N., Mowles, D., Peng, Y., Robins, M. J., Cass, C. E., & Gros, P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5528 · Cited by 93
CF102 for the Treatment of Hepatocellular Carcinoma: A Phase I/II, Open-Label, Dose-Escalation Study
Stemmer, S. M., Benjaminov, O., Medalia, G., Ciuraru, N. B., Silverman, M. H., Bar‐Yehuda, S., Fishman, S., Harpaz, Z., Farbstein, M., Cohen, S., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0211 · Cited by 93
Stefañska, B., Rudnicka, K., Bednarek, A. K., & Fabianowska‐Majewska, K. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.04.032 · Cited by 92
Brueckner, B., Rius, M., Markelova, M. R., Fichtner, I., Hals, P., Sandvold, M. L., & Lyko, F. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1202 · Cited by 92
The role of floxuridine in metastatic liver disease
Power, D. G., & Kemeny, N. E. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0709 · Cited by 92
Huang, P., Sandoval, A., Neste, E. V. D., et al. (2000) · Leukemia · doi:10.1038/sj.leu.2401845 · Cited by 91
Saeki, N., Ono, H., Sakamoto, H., & Yoshida, T. (2012) · Cancer Science · doi:10.1111/cas.12042 · Cited by 91
Moussay, E., Palissot, V., Vallar, L., Poirel, H. A., Wenner, T., El‐Khoury, V., Aouali, N., Moer, K. V., Leners, B., Bernardin, F., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-115 · Cited by 91
Differential ectonucleotidase expression in human bladder cancer cell lines
Stella, J., Bavaresco, L., Braganhol, E., Rockenbach, L., Farias, P. F., Wink, M. R., Azambuja, A. A., Barrios, C. H., Morrone, F. B., & Battastini, A. M. O. (2009) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2009.01.035 · Cited by 90
Kukhanova, M. K., Liu, S.-H., Mozzherin, D. J., Lin, T., Chu, C. K., & Cheng, Y. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.39.23055 · Cited by 87
Srivastava, P., Paluch, B. E., Matsuzaki, J., James, S. R., Collamat, G., Karbach, J., Nemeth, M. J., Taverna, P., Karpf, A. R., & Griffiths, E. A. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.09.001 · Cited by 87
Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?
Sun, C., Ansari, D., Andersson, R., & Wu, D.-Q. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i35.4944 · Cited by 87
Reiser, H., Wang, J., Chong, L., Watkins, W. J., Ray, A. S., Shibata, R., Birkuš, G., Cihlář, T., Wu, S., Li, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2061 · Cited by 87
Jin, H., Liao, L., Park, Y., & Liu, Y. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213819110 · Cited by 86
Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs
Serdjebi, C., Milano, G. A., & Ciccolini, J. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.985648 · Cited by 85
Advances in cancer immunology and cancer immunotherapy.
Voena, C., & Chiarle, R. (2016) · PubMed · Cited by 85
A Gatekeeper Residue for NEDD8-Activating Enzyme Inhibition by MLN4924
Toth, J. I., Yang, L., Dahl, R. S., & Petroski, M. D. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.02.006 · Cited by 84
Matsuda, A., Nakajima, Y., Azuma, A., Tanaka, M., & Sasaki, T. (1991) · Journal of Medicinal Chemistry · doi:10.1021/jm00113a034 · Cited by 84
Basavapathruni, A., Olhava, E. J., Daigle, S. R., Therkelsen, C. A., Jin, L., Boriack‐Sjodin, P. A., Allain, C. J., Klaus, C. R., Raimondi, A., Scott, M. P., et al. (2014) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1889 · Cited by 83
Selective Anti-Herpesvirus Agents
Clercq, E. D. (2013) · Antiviral chemistry & chemotherapy · doi:10.3851/imp2533 · Cited by 83
MicroRNA-320a promotes 5-FU resistance in human pancreatic cancer cells
Wang, W., Zhao, L., Wei, X., Wang, L., Liu, S., Yang, Y. P., Wang, F., Sun, G., Zhang, J., Ma, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep27641 · Cited by 83
Balakrishnan, K., Nimmanapalli, R., Ravandi, F., Keating, M. J., & Gandhi, V. V. (2006) · Blood · doi:10.1182/blood-2006-03-007468 · Cited by 82
Guo, Y., Köck, K., Ritter, C. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0442 · Cited by 82
Mechanisms for T-cell selective cytotoxicity of arabinosylguanine
Rodriguez, C. O., Stellrecht, C. M., & Gandhi, V. V. (2003) · Blood · doi:10.1182/blood-2003-01-0317 · Cited by 82
Gourdeau, H., Clarke, M. L., Ouellet, F., Mowles, D., Selner, M., Richard, A., Lee, N. J., Mackey, J. R., Young, J. D., Jolivet, J., et al. (2001) · PubMed · Cited by 81
Cytomegalovirus and brain tumor: epidemiology, biology and therapeutic aspects
Cobbs, C. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000005 · Cited by 81
Uracil in DNA: Consequences for carcinogenesis and chemotherapy
Berger, S. H., Pittman, D. L., & Wyatt, M. D. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.05.019 · Cited by 80
Garrett, C. R., Coppola, D., Wenham, R. M., Cubitt, C. L., Neuger, A. M., Frost, T. J., Lush, R. M., Sullivan, D. M., Cheng, J. Q., & Sebti, S. M. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9479-2 · Cited by 79
11q23/MLL Acute Leukemia : Update of Clinical Aspects
Tamai, H., & Inokuchi, K. (2010) · Journal of the Japan Society of the Reticuloendothelial System · doi:10.3960/jslrt.50.91 · Cited by 79
New combination therapies with cell-cycle agents.
Deep, G., & Agarwal, R. (2008) · PubMed · Cited by 78
Differential toxic effects of azathioprine, 6-mercaptopurine and 6-thioguanine on human hepatocytes
Petit, E., Langouët, S., Akhdar, H., Nicolaz, C. N., Guillouzo, A., & Morel, F. (2007) · Toxicology in Vitro · doi:10.1016/j.tiv.2007.12.004 · Cited by 78
Cohen, S., Stemmer, S. M., Zozulya, G., Ochaion, A., Patoka, R., Barer, F., Bar‐Yehuda, S., Rath‐Wolfson, L., Jacobson, K. A., & Fishman, P. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22593 · Cited by 78
Landowski, C. P., Song, X., Lorenzi, P. L., Hilfinger, J. M., & Amidon, G. L. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-6156-9 · Cited by 78
Duxbury, M. S., Ito, H., Benoit, E., Waseem, T., Ashley, S. W., & Whang, E. E. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1510 · Cited by 78
Giles, F. J., Garcia-Manero, G., Cortes, J. E., Baker, S. D., Miller, C. B., O'Brien, S. M., Thomas, D. A., Andreeff, M., Bivins, C., Jolivet, J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.656 · Cited by 78
Flaßhove, M., Strumberg, D., Ayscue, L. H., Mitchell, B. S., Tirier, C., Heit, W. F. W., Seeber, S., & Schütte, J. (1994) · PubMed · Cited by 77
A Medicinal Chemistry Perspective for Targeting Histone H3 Lysine-79 Methyltransferase DOT1L
Anglin, J. L., & Song, Y. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4007752 · Cited by 76
The clinical pharmacology of 5-trifluoromethyl-2'-deoxyuridine.
Dexter, D. L., Wolberg, W. H., Ansfield, F. J., Helson, L., & Heidelberger, C. (1972) · PubMed · Cited by 76
Immunomodulatory activity of SGI-110, a 5-aza-2′-deoxycytidine-containing demethylating dinucleotide
Coral, S., Parisi, G., Nicolay, H. J. M., Colizzi, F., Danielli, R., Fratta, E., Covre, A., Taverna, P., Sigalotti, L., & Maio, M. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1365-7 · Cited by 76
Madi, L., Cohen, S., Ochayin, A., Bar‐Yehuda, S., Barer, F., & Fishman, P. (2007) · PubMed · Cited by 76
Purine Nucleoside Phosphorylase Deficiency
Osborne, W. R. A., Chen, S.-H., Giblett, E. R., Biggar, W. D., Ammann, A. A., & Scott, C. R. (1977) · Journal of Clinical Investigation · doi:10.1172/jci108826 · Cited by 75
Costa, C., Pereira, S., Lima, L., Peixoto, A., Fernandes, E., Neves, D., Neves, M., Gaiteiro, C., Tavares, A., da Costa, R. M. G., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141253 · Cited by 73
Chutes and ladders in hepatitis C nucleoside drug development
Coats, S. J., Garnier‐Amblard, E. C., Amblard, F., Ehteshami, M., Amiralaei, S., Zhang, H., Zhou, L., Bouclé, S., Lu, X., Bondada, L., et al. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.11.008 · Cited by 72
Self-citationFludarabine: A review of the clear benefits and potential harms
Lukenbill, J., & Kalaycio, M. E. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.05.004 · Cited by 72
Do Corticosteroids Provide Analgesic Effects in Cancer Patients? A Systematic Literature Review
Paulsen, Ø., Aass, N., Kaasa, S., & Dale, O. (2012) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2012.06.019 · Cited by 72
Rodriguez, C. O., Mitchell, B. S., Ayres, M., Eriksson, S., & Gandhi, V. V. (2002) · PubMed · Cited by 71
dUTPase activity is critical to maintain genetic stability in Saccharomyces cerevisiae
Guillet, M. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl139 · Cited by 71
Luo, Z., Pan, Y., Jeong, L. S., Liu, J., & Jia, L. (2012) · Autophagy · doi:10.4161/auto.21484 · Cited by 70
Modrak, D. E., Cardillo, T. M., Newsome, G., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2988 · Cited by 68
Yoo, J., Choi, S., & Medina‐Franco, J. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062152 · Cited by 68
Cladribine: not just another purine analogue?
Spurgeon, S. E. F., Yu, M. K., Phillips, J. D., & Epner, E. M. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903071038 · Cited by 68
Discontinued in 2013: oncology drugs
Williams, R. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.971154 · Cited by 67
Ebrahem, Q., Mahfouz, R. Z., Ng, K. P., & Saunthararajah, Y. (2012) · Oncotarget · doi:10.18632/oncotarget.597 · Cited by 66
Holbein, S., Wengi, A., Decourty, L., Freimoser, F. M., Jacquier, A., & Dichtl, B. (2009) · RNA · doi:10.1261/rna.1458909 · Cited by 66
Xie, X., Liu, H., Wang, Y., Zhou, Y., Yu, H., Li, G., Ruan, Z., Li, F., Wang, X., & Zhang, J. (2016) · Oncotarget · doi:10.18632/oncotarget.9962 · Cited by 66
The Role of Membrane Transporters in Cellular Resistance to Anticancer Nucleoside Drugs
Clarke, M. L., Mackey, J. R., Baldwin, S. A., Young, J. D., & Cass, C. E. (2002) · Cancer treatment and research · doi:10.1007/978-1-4615-1173-1_2 · Cited by 65
Guchelaar, H., Vermes, I., Koopmans, R. P., Reutelingsperger, C. P. M., & Haanen, C. (1998) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050788 · Cited by 65
Recent syntheses of PI3K/Akt/mTOR signaling pathway inhibitors
Welker, M. E., & Kulik, G. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.04.083 · Cited by 63
The nucleoside antagonist cordycepin causes DNA double strand breaks in breast cancer cells
Lee, H. J., Burger, P., Vogel, M., Friese, K., & Brüning, A. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9859-x · Cited by 63
Tatum, D. M., & Li, S. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.241570 · Cited by 62
Beumer, J. H., Eiseman, J. L., Parise, R. A., Joseph, E., Holleran, J. L., Covey, J. M., & Egorin, M. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1250 · Cited by 62
Improving Gemcitabine-Mediated Radiosensitization Using Molecularly Targeted Therapy: A Review
Morgan, M. A., Parsels, L. A., Maybaum, J., & Lawrence, T. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1032 · Cited by 62
Chan, E., Putt, S. R., Showalter, H. D. H., & Baker, D. C. (1982) · The Journal of Organic Chemistry · doi:10.1021/jo00139a015 · Cited by 61
Identification of in Vivo Phosphorylation Sites on Human Deoxycytidine Kinase
Smal, C., Vertommen, D., Bertrand, L., Ntamashimikiro, S., Rider, M. H., Neste, E. V. D., & Bontemps, F. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m512129200 · Cited by 60
Galiñanes, M., Bullough, D. A., Mullane, K., & Hearse, D. J. (1992) · Circulation · doi:10.1161/01.cir.86.2.589 · Cited by 59
Walsby, E. J., Coles, S., Knapper, S., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.032680 · Cited by 59
Newman, E. M., Morgan, R. J., Kummar, S., Beumer, J. H., Blanchard, M. S., Ruel, C., El-Khoueiry, A. B., Carroll, M. I., Hou, J., Li, C., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2674-7 · Cited by 59
Liu, X., Guo, Y., Li, Y., Jiang, Y., Chubb, S., Azuma, A., Huang, P., Matsuda, A., Hittelman, W. N., & Plunkett, W. K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0288 · Cited by 59
de Silva, S., Wang, F., Hake, T. S., Porcu, P., Wong, H. K., & Wu, L. J. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.311 · Cited by 58
Ferraris, D. V., Duvall, B. R., Delahanty, G., Mistry, B., Alt, J., Rojas, C. J., Rowbottom, C., Sanders, K., Schuck, E. L., Huang, K.-C., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401856k · Cited by 58
Yano, S., Kazuno, H., Sato, T., Suzuki, N., Emura, T., Wierzba, K., Yamashita, J., Tada, Y., Yamada, Y., Fukushima, M., et al. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.04.046 · Cited by 55
SGI‐110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome
Tellez, C. S., Grimes, M. J., Picchi, M. A., Liu, Y., March, T. H., Reed, M. D., Oganesian, A., Taverna, P., & Belinsky, S. A. (2014) · International Journal of Cancer · doi:10.1002/ijc.28865 · Cited by 54
New procedure for the chlorination of pyrimidine and purine nucleosides
Ryu, E. K., & MacCoss, M. (1981) · The Journal of Organic Chemistry · doi:10.1021/jo00326a053 · Cited by 54
Eckstein, J. W., Foster, P., Finer-Moore, J. S., et al. (1994) · Biochemistry · doi:10.1021/bi00254a018 · Cited by 54
Huehls, A. M., Huntoon, C. J., Joshi, P. M., Baehr, C., Wagner, J. M., Wang, X., Lee, M. Y., & Karnitz, L. M. (2015) · Molecular Pharmacology · doi:10.1124/mol.115.100164 · Cited by 53
Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126
Adema, A. D., Smid, K., Losekoot, N., Honeywell, R. J., Verheul, H. M. W., Myhren, F., Sandvold, M. L., & Peters, G. J. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9756-8 · Cited by 52
Oral Clofarabine in the Treatment of Patients With Higher-Risk Myelodysplastic Syndrome
Faderl, S. H., Garcia‐Manero, G., Estrov, Z. E., Ravandi, F., Borthakur, G. M., Cortes, J. E., O'Brien, S. M., Gandhi, V. V., Plunkett, W. K., Byrd, A. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3509 · Cited by 51
Koolen, S. L. W., Witteveen, P. O., Jansen, R. S., Langenberg, M. H. G., Kronemeijer, R. H., Nol, A., Garcia‐Ribas, I., Callies, S., Benhadji, K. A., Slapak, C. A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0353 · Cited by 51
FLUORINATED PYRIMIDINES. XXI. THE TUMOR-INHIBITORY ACTIVITY OF 5-TRIFLUOROMETHYL-2'-DEOXYURIDINE.
Heidelberger, C., & Anderson, S. W. (1964) · PubMed · Cited by 49
Kopadze, T., Döbert, M., Leussink, V. I., Dehmel, T., & Kieseier, B. C. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2008.02433.x · Cited by 49
Serdjebi, C., Seitz, J., Ciccolini, J., Duluc, M., Norguet, E., Fina, F., Lacarelle, B., Ouafik, L., & Dahan, L. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.93 · Cited by 49
Gandhi, V. V., Keating, M. J., Bate, G., & Kirkpatrick, P. N. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1933 · Cited by 49
Balakrishnan, K., Stellrecht, C. M., Genini, D., Ayres, M., Wierda, W. G., Keating, M. J., Leoni, L. M., & Gandhi, V. V. (2005) · Blood · doi:10.1182/blood-2004-05-1699 · Cited by 48
Hummel-Eisenbeiss, J., Hascher, A., Hals, P., Sandvold, M. L., Müller‐Tidow, C., Lyko, F., & Rius, M. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.086801 · Cited by 48
Shen, B., & Jamison, T. F. (2012) · Organic Letters · doi:10.1021/ol301324g · Cited by 48
Mode of action of trifluorothymidine (TFT) against DNA replication and repair enzymes
Suzuki, N. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1003 · Cited by 47
Schram, K. H., & Townsend, L. B. (1971) · Tetrahedron Letters · doi:10.1016/s0040-4039(01)87546-8 · Cited by 47
p38MAPK and Chemotherapy: We Always Need to Hear Both Sides of the Story
García‐Cano, J., Roche, O., Cimas, F. J., Pascual‐Serra, R., Ortega‐Muelas, M., Fernández‐Aroca, D. M., & Sánchez‐Prieto, R. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00069 · Cited by 47
H-Gemcitabine: A New Gemcitabine Prodrug for Treating Cancer
Dasari, M., Acharya, A. P., Kim, D., et al. (2012) · Bioconjugate Chemistry · doi:10.1021/bc300095m · Cited by 46
Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma
Ravandi, F., & Gandhi, V. V. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.12.1601 · Cited by 46
Pathway Implications of Aberrant Global Methylation in Adrenocortical Cancer
Legendre, C., Demeure, M. J., Whitsett, T. G., Gooden, G. C., Bussey, K. J., Jung, S., Tembe, W., Kim, S., & Salhia, B. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150629 · Cited by 46
Heidelberger, C., Boohar, J., & Kampschroer, B. H. (1965) · PubMed · Cited by 45
Wang, Q., Li, S.-H., Wang, H., Xiao, Y. Q., Şahin, Ö., Brady, S. W., Li, P., Ge, H., Jaffee, E. M., Muller, W. J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1339-t · Cited by 45
Arnold, L. H., Kunzelmann, S., Webb, M. R., & Taylor, I. A. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03903-14 · Cited by 45
Tsume, Y., İnceçayır, T., Song, X., Hilfinger, J. M., & Amidon, G. L. (2013) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2013.12.009 · Cited by 44
An epigenetic mechanism for capecitabine resistance in mesothelioma
Kosuri, K. V., Wu, X., Wang, L., Villalona-Calero, M. A., & Otterson, G. A. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.12.095 · Cited by 44
CD73-adenosine reduces immune responses and survival in ovarian cancer patients
Gaudreau, P.-O., Allard, B., Turcotte, M., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1127496 · Cited by 44
Ko, Y.-J., & Karanicolas, P. J. (2013) · Current Oncology · doi:10.3747/co.21.1592 · Cited by 43
Ahn, Y., Jung, J. M., & Hong, S. H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3122 · Cited by 43
Multiple Myeloma Cell Killing by Depletion of the MET Receptor Tyrosine Kinase
Stellrecht, C. M., Phillip, C. J., Cervantes-Gomez, F., & Gandhi, V. V. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0770 · Cited by 43
Boyer, S. H., Sun, Z., Jiang, H., Esterbrook, J., Gomez‐Galeno, J., Craigo, W. A., Reddy, K. R., Ugarkar, B. G., MacKenna, D. A., & Erion, M. D. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0607449 · Cited by 43
Shanmugam, M., McBrayer, S. K., Qian, J., Raikoff, K., Avram, M. J., Singhal, S., Gandhi, V. V., Schumacker, P. T., Krett, N. L., & Rosen, S. T. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.000646 · Cited by 42
G9a orchestrates PCL3 and KDM7A to promote histone H3K27 methylation
Pan, M., Hsu, M., Chen, L., & Hung, W. (2015) · Scientific Reports · doi:10.1038/srep18709 · Cited by 42
New nucleoside analogs for patients with hematological malignancies
Robak, T. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.554822 · Cited by 41
dNTP pool modulation dynamics by SAMHD1 protein in monocyte-derived macrophages
Hollenbaugh, J. A., Tao, S., Lenzi, G. M., Ryu, S., Kim, D., Diaz‐Griffero, F., Schinazi, R. F., & Kim, B. (2014) · Retrovirology · doi:10.1186/preaccept-5624405321277583 · Cited by 41
Self-citationEpigenetic synergy between decitabine and platinum derivatives
Qin, T., Si, J., Raynal, N. J. ‐., Wang, X., Gharibyan, V., Ahmed, S., Hu, X., Jin, C., Lu, Y., Shu, J., et al. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0131-z · Cited by 41
Peters, G. J., Smid, K., Vecchi, L., Kathmann, I., Sarkisjan, D., Honeywell, R. J., Losekoot, N., Ohne, O., Orbach, A., Blaugrund, E., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-0025-x · Cited by 40
Kramata, P., Downey, K. M., & Paborsky, L. R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.34.21966 · Cited by 40
Stellrecht, C. M., Vangapandu, H. V., Le, X., Mao, W., & Shentu, S. (2014) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-7-23 · Cited by 40
Trifluorothymidine exhibits potent antitumor activity via the induction of DNA double-strand breaks
SUZUKI, N., Nakagawa, F., Nukatsuka, M., & Fukushima, M. (2011) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2011.244 · Cited by 39
Sponges, Cancer Chemotherapy, and Cellular Aging
Cohen, S. S. (1963) · Perspectives in biology and medicine · doi:10.1353/pbm.1963.0032 · Cited by 39
Voorde, J. V., Liekens, S., McGuigan, C., Murziani, P. G. S., Ślusarczyk, M., & Balzarini, J. M. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.05.024 · Cited by 39
DNA Methylation of Tumor Suppressor Protein-Coding and Non-Coding Genes in Multiple Myeloma
Wong, K. Y., & Chim, C. S. (2015) · Epigenomics · doi:10.2217/epi.15.57 · Cited by 38
Phua, L. C., Mal, M., Koh, P. K., Cheah, P. Y., Chan, E. C. Y., & Ho, H. K. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2054-0 · Cited by 38
Harnessing gemcitabine metabolism: a step towards personalized medicine for pancreatic cancer
Saif, M. W., Lee, Y., & Kim, R. D. (2012) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834012453755 · Cited by 38
New Challenges and Inspired Answers for Anticancer Drug Discovery and Development
Utsugi, T. (2013) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyt131 · Cited by 38
Lang, T. T., Young, J. D., & Cass, C. E. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.4.925 · Cited by 37
Chen, L. S., & Sheppard, T. L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401752200 · Cited by 37
Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors
Stuurman, F. E., Voest, E. E., Awada, A. H., Witteveen, P. O., Bergeland, T., Hals, P., Rasch, W., Schellens, J. H. M., & Hendlisz, A. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9925-z · Cited by 36
Lubecka, K., Kaufman‐Szymczyk, A., Stefañska, B., Cebula‐Obrzut, B., Smolewski, P., & Fabianowska‐Majewska, K. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.11.021 · Cited by 36
Oral fluoropyrimidine anticancer drug TS-1 for gastric cancer patients with peritoneal dissemination
Osugi, H., Takada, N., Takemura, M., Kaseno, S., Lee, S., Ueno, M., Tanaka, Y., Fukuhara, K., Fujiwara, Y., & Kinoshita, H. (2002) · Oncology Reports · doi:10.3892/or.9.4.811 · Cited by 36
Metabolism of 4′-thio-β-d-arabinofuranosylcytosine in CEM cells
Parker, W. B., Shaddix, S. C., Rose, L. M., Waud, W. R., Shewach, D. S., Tiwari, K. N., & Secrist, J. A. I. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00520-7 · Cited by 36
Qi, W., Tang, L., He, A., Shen, Z., Lin, F., & Yao, Y. (2012) · Lung · doi:10.1007/s00408-012-9399-3 · Cited by 36
Oral decitabine reactivates expression of the methylated γ‐globin gene in Papio anubis
Lavelle, D., Chin, J., Vaitkus, K., Redkar, S., Phiasivongsa, P., Tang, C., Will, R., Hankewych, M., Roxas, B. P., Singh, M., et al. (2007) · American Journal of Hematology · doi:10.1002/ajh.21020 · Cited by 35
Holm, N. T., Byrnes, K., Johnson, L., Abreo, F. W., Sehon, K., Alley, J., Meschonat, C., Chu, Q. D., & Li, B. D. �. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-0086-9 · Cited by 35
2-Chlorodeoxyadenosine (cladribine) induces apoptosis in human monocyte-derived dendritic cells
Singh, V., Prajeeth, C. K., Gudi, V., Bénardais, K., Voß, E. V., & Stangel, M. (2013) · Clinical & Experimental Immunology · doi:10.1111/cei.12109 · Cited by 33
Cytosolic 5′-nucleotidase III (NT5C3): gene sequence variation and functional genomics
Aksoy, P., Zhu, M., Kalari, K. R., Moon, I., Pelleymounter, L. L., Eckloff, B. W., Wieben, E. D., Yee, V. C., Weinshilboum, R. M., & Wang, L. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32832c14b8 · Cited by 33
Mehellou, Y., Valente, R., Mottram, H. J., Walsby, E. J., Mills, K., Balzarini, J. M., & McGuigan, C. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.02.059 · Cited by 33
Stellrecht, C. M., Ayres, M., Arya, R., & Gandhi, V. V. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0481-3 · Cited by 33
Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine
Muggia, F. M., Diaz, I., & Peters, G. J. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.666236 · Cited by 32
Human cytidine deaminase: A biochemical characterization of its naturally occurring variants
Micozzi, D., Carpi, F. M., Pucciarelli, S., Polzonetti, V., Polidori, P., Vilar, S., Williams, B., Costanzi, S., & Vincenzetti, S. (2013) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2013.10.029 · Cited by 32
Matúšková, M., Baranovičová, L., Kozovská, Z., Durinikova, E., Pastorakova, A., Hunáková, Ľ., Waczulíková, I., Nencka, R., & Kučerová, L. (2012) · The Journal of Gene Medicine · doi:10.1002/jgm.2684 · Cited by 32
Libra, M., Navolanic, P. M., Talamini, R., Cecchin, E., Sartor, F., Tumolo, S., Masier, S., Travali, S., Boiocchi, M., & Toffoli, G. (2004) · BMC Cancer · doi:10.1186/1471-2407-4-11 · Cited by 31
A pharmacological activator of AMP-activated protein kinase (AMPK) induces astrocyte stellation
Favero, C. B., & Mandell, J. W. (2007) · Brain Research · doi:10.1016/j.brainres.2007.06.087 · Cited by 31
Pratt, S. E., Durland–Busbice, S., Shepard, R. L., Donoho, G. P., Starling, J. J., Wickremsinhe, E. R., Perkins, E. J., & Dantzig, A. H. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0654 · Cited by 31
Kaysen, J. H., Spriggs, D. R., & Kufe, D. W. (1986) · PubMed · Cited by 30
New Trends in the Standard of Care for Initial Therapy of Acute Myeloid Leukemia
Fernandez, H. F. (2010) · Hematology · doi:10.1182/asheducation-2010.1.56 · Cited by 30
Al-Salihi, M. A., Yu, M. K., Burnett, D. M., Alexander, A., Samlowski, W. E., & Fitzpatrick, F. A. (2011) · Epigenetics · doi:10.4161/epi.6.8.16064 · Cited by 29
Meike, S., Yamamori, T., Yasui, H., Eitaki, M., Matsuda, A., Morimatsu, M., Fukushima, M., Yamasaki, Y., & Inanami, O. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-92 · Cited by 29
Guo, Y., Shi, M., Shen, X., Chen, Y., Yang, L., & Zhang, J. (2014) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2013.12.004 · Cited by 29
Thottassery, J. V., Westbrook, L., Someya, H., & Parker, W. B. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0409 · Cited by 29
Waters, N. J., Daigle, S. R., Rehlaender, B. N., Basavapathruni, A., Campbell, C. T., Jensen, T. B., Truitt, B. F., Olhava, E. J., Pollock, R. M., Stickland, K., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.023 · Cited by 28
Levinsen, M., Rotevatn, E. Ø., Rosthøj, S., Nersting, J., Abrahamsson, J., Appell, M. L., Bergan, S., Bechensteen, A. G., Harila‐Saari, A. H., Heyman, M. M., et al. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.24921 · Cited by 28
Liu, X., Wang, Y., Benaissa, S., Matsuda, A., Kantarjian, H. M., Estrov, Z. E., & Plunkett, W. K. (2010) · Blood · doi:10.1182/blood-2009-05-220376 · Cited by 28
Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human
Waters, N. J., Smith, S. A., Olhava, E. J., Duncan, K. W., Burton, R. D., O’Neill, J., Rodrigue, M.-È., Pollock, R. M., Moyer, M. P., & Chesworth, R. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2929-y · Cited by 28
Stereoselective Synthesis of MLN4924, an Inhibitor of NEDD8-Activating Enzyme
Lee, H. W., Nam, S. K., Choi, W. J., Kim, H. O., & Jeong, L. S. (2011) · The Journal of Organic Chemistry · doi:10.1021/jo2001897 · Cited by 28
Yanik, E. L., Tamburro, K. M., Eron, J. J., Damania, B., Napravnik, S., & Dittmer, D. P. (2013) · Infectious Agents and Cancer · doi:10.1186/1750-9378-8-18 · Cited by 27
Hepatic Arterial Infusion of Chemotherapy for Hepatic Metastases from Colorectal Cancer
Homsi, J., & Garrett, C. R. (2006) · Cancer Control · doi:10.1177/107327480601300106 · Cited by 26
Clinical utility of nivolumab in the treatment of advanced melanoma
Carvajal, R. D., Asmar, R., & Yang, J. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s78039 · Cited by 26
Dual mechanisms of inhibition of DNA synthesis by triciribine.
Wotring, L. L., Townsend, L. B., Jones, L. M., Borysko, K. Z., Gildersleeve, D. L., & Parker, W. B. (1990) · PubMed · Cited by 25
Activation of the serine/threonine protein kinase Akt during the progression of Barrett neoplasia
Sagatys, E. M., Garrett, C. R., Boulware, D. C., Kelley, S., Malafa, M. P., Cheng, J. Q., Sebti, S. M., & Coppola, D. (2007) · Human Pathology · doi:10.1016/j.humpath.2007.03.003 · Cited by 25
Liu, X., Kantarjian, H. M., & Plunkett, W. K. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.660249 · Cited by 25
Kramata, P., & Downey, K. M. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12392-9 · Cited by 24
Holleran, J. L., Beumer, J. H., McCormick, D. L., Johnson, W. D., Newman, E. M., Doroshow, J. H., Kummar, S., Covey, J. M., Davis, M., & Eiseman, J. L. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2857-x · Cited by 23
Molecular insight into thiopurine resistance: transcriptomic signature in lymphoblastoid cell lines
Chouchana, L., Fernández-Ramos, A. A., Dumont, F., Marchetti, C., Ceballos-Picot, I., Beaune, P. H., Gurwitz, D., & Loriot, M. (2015) · Genome Medicine · doi:10.1186/s13073-015-0150-6 · Cited by 23
Hypoxia-Induced Cytosine Deaminase Gene Expression for Cancer Therapy
Lee, C., Wu, C., & Shiau, A. (2007) · Human Gene Therapy · doi:10.1089/hum.2005.239 · Cited by 23
Wang, Y., Liu, X., Matsuda, A., & Plunkett, W. K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6885 · Cited by 23
Phase II study of troxacitabine in chemotherapy-naïve patients with advanced cancer of the pancreas
Lapointe, R. W., Letourneau, R., Steward, W. P., Hawkins, R. E., Batist, G., Vincent, M., Whittom, R., Eatock, M. M., Jolivet, J., & Moore, M. J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi061 · Cited by 23
The druggability of intracellular nucleotide-degrading enzymes
Rampazzo, C., Tozzi, M. G., Dumontet, C., & Jordheim, L. P. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2921-6 · Cited by 23
Clinical Trials in ALS: What Did We Learn from Recent Trials in Humans?
Meininger, V. (2005) · Neurodegenerative Diseases · doi:10.1159/000089627 · Cited by 22
Safety, Tolerability, and Efficacy of Oral Therapies for Relapsing-Remitting Multiple Sclerosis
Oh, J., & O'Connor, P. W. (2013) · CNS Drugs · doi:10.1007/s40263-013-0080-z · Cited by 22
Jansen, R. S., Rosing, H., Wijermans, P., Keizer, R. J., Schellens, J. H. M., & Beijnen, J. H. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1850-x · Cited by 21
Someya, H., Shaddix, S. C., Tiwari, K. N., Secrist, J. A. I., & Parker, W. B. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045435 · Cited by 21
Wickremsinhe, E. R., Lutzke, B. S., Jones, B. R., Schultz, G. A., Freeman, A. B., Pratt, S. E., Bones, A. M., & Ackermann, B. L. (2010) · Analytical Chemistry · doi:10.1021/ac100984h · Cited by 20
Montraveta, A., Xargay‐Torrent, S., López‐Guerra, M., Rosich, L., Pérez‐Galán, P., Salaverría, I., Beà, S., Kalko, S. G., de Frías, M., Campàs, C., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1455 · Cited by 19
Pepper, C. J., Lowe, H. L., Fegan, C., Thurieau, C., Thurston, D. E., Hartley, J. A., & Delavault, P. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603853 · Cited by 19
Systemic treatment for inoperable pancreatic adenocarcinoma: review and update
Chan, S. L., Chan, S. T., Chan, E. H., & He, Z. (2014) · 癌症:英文版 · doi:10.5732/cjc.013.10134 · Cited by 19
Ross, D. D., Cuddy, D. P., Cohen, N. A., & Hensley, D. R. (1992) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00695996 · Cited by 19
McBrayer, S. K., Yarrington, M. E., Qian, J., Feng, G., Shanmugam, M., Gandhi, V. V., Krett, N. L., & Rosen, S. T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041455 · Cited by 18
Absolute Quantification of E1, Ubiquitin-Like Proteins and Nedd8–MLN4924 Adduct by Mass Spectrometry
Yang, X., Brownell, J., Xu, Q., Zhu, F., Ma, J.-Y., Loke, H., Rollins, N., Soucy, T. A., Minissale, J., Thomas, M. P., et al. (2013) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-013-9625-5 · Cited by 17
Rossi, D. (2014) · Blood · doi:10.1182/blood-2013-12-545384 · Cited by 17
Hodge, L. S., Taub, M. E., & Tracy, T. S. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040790 · Cited by 17
Beumer, J. H., Joseph, E., Egorin, M. J., Covey, J. M., & Eiseman, J. L. (2005) · Journal of Chromatography B · doi:10.1016/j.jchromb.2005.11.048 · Cited by 16
Li, C., Gu, Y., Zhao, M. D., Yuan, Y., Wang, F., Wang, Z., Li, W., Luo, H., Chen, C., Chen, G., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2585-7 · Cited by 15
Troxacitabine Prodrugs for Pancreatic Cancer
Adema, A. D., Radi, M., Daft, J. R., Narayanasamy, J., Hoebe, E. K., Alexander, L. E., CHU, C. K., & Peters, G. J. (2007) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1080/15257770701515591 · Cited by 15
Efficacy of Oral Anticancer Agents for Colorectal Cancer
Sakamoto, J., Oba, K., Matsui, T., & Kobayashi, M. (2006) · Diseases of the Colon & Rectum · doi:10.1007/s10350-006-0601-7 · Cited by 15
Zhao, T., Xu, Z., Gu, D., Wu, P., Huo, X., Wei, X., Tang, Y., Gong, W., He, M., & Chen, J. (2016) · Scientific Reports · doi:10.1038/srep28019 · Cited by 15
Preclinical studies of 5-fluoro-2′-deoxycytidine and tetrahydrouridine in pediatric brain tumors
Morfouace, M., Nimmervoll, B. V., Boulos, N., Patel, Y. T., Shelat, A. A., Freeman, B. B., Robinson, G. W., Wright, K. D., Gajjar, A. J., Stewart, C. F., et al. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1965-0 · Cited by 14
Someya, H., Waud, W. R., & Parker, W. B. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0126-0 · Cited by 14
Wu, Q., Wang, X., Liu, J., Zheng, J., Liu, Y., Li, Y., Su, F., Ou, W., & Wang, R. (2016) · Oncology Reports · doi:10.3892/or.2016.4920 · Cited by 14
Vose, J. M., Panwalkar, A. W., Bélanger, R., Coiffier, B., Baccarani, M., Gregory, S. A., Facon, T. T. F., Fanin, R., Caballero, D. M., Ben‐Yehuda, D., et al. (2007) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190600909578 · Cited by 12
Emerging mitotic inhibitors for non-small cell carcinoma
Casaluce, F., Sgambato, A., Maione, P., Ciardiello, F., & Gridelli, C. (2013) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2013.777426 · Cited by 12
Coucke, P. A., Cottin, E., & Decosterd, L. A. (2007) · Acta Oncologica · doi:10.1080/02841860601137389 · Cited by 11
Hammond-Thelin, L. A., Thomas, M. B., Iwasaki, M., Abbruzzese, J. L., Lassere, Y., Meyers, C. A., Hoff, P. M., Bono, J. S. D., Norris, J., Matsushita, H., et al. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9535-y · Cited by 11
LC–MS/MS assay for the quantitation of FdCyd and its metabolites FdUrd and FU in human plasma
Holleran, J. L., Eiseman, J. L., Parise, R. A., et al. (2016) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2016.07.027 · Cited by 11
Current Approaches to Epigenetic Therapy for the Treatment of Mantle Cell Lymphoma
Ghai, V., Sharma, K., Abbi, K. K. S., Shimko, S., & Epner, E. M. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-6176-0_11 · Cited by 9
Traitement des maladies inflammatoires chroniques de l’intestin
Lémann, M. (2007) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)32983-8 · Cited by 8
Bruheim, S., Sandvold, M. L., Mælandsmo, G. M., & Fodstad, Ø. (2013) · PubMed · Cited by 8
Ectonucleotidases in Solid Organ and Allogeneic Hematopoietic Cell Transplantation
Chernogorova, P., & Zeiser, R. (2012) · BioMed Research International · doi:10.1155/2012/208204 · Cited by 8
Goss, G. D., Siu, L. L., Gauthier, I., Chen, E. X., Oza, A. M., Goel, R., Maroun, J., Powers, J., Walsh, W. R., Maclean, M., et al. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0201-1 · Cited by 8
Lee, C. P., de Jonge, M. J. A., O'Donnell, A. E., Schothorst, K. L., Hanwell, J., Chick, J., Brooimans, R. A., Adams, L. M., Drolet, D. W., Bono, J. S. D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1932 · Cited by 8
PENG, X.-X., Shi, Z., Tiwari, A. K., Damaraju, V. L., Fu, L., Cass, C. E., Ashby, C. R., Kruh, G. D., & Chen, Z. (2011) · Oncology Letters · doi:10.3892/ol.2011.288 · Cited by 7
Prevention of human papillomavirus-related diseases: Impediments to progress
Zimet, G. D., & Buffler, P. A. (2013) · Preventive Medicine · doi:10.1016/j.ypmed.2013.08.005 · Cited by 5
Lawrence, J., Huelsmeyer, M. K., Thamm, D. H., Tumas, D. B., Birkuš, G., Kurzman, I. D., & Vail, D. M. (2013) · Veterinary and Comparative Oncology · doi:10.1111/vco.12038 · Cited by 5
Expression of Pyrimidine Nucleoside Phosphorylase (PyNPase) in Colorectal Cancer
Osanai, T. (2001) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hye108 · Cited by 4
Phosphonated Nucleoside Analogues
Romeo, R., Carnovale, C., Rescifina, A., & Chiacchio, M. A. (2013) · Wiley eBooks · doi:10.1002/9781118498088.ch4 · Cited by 3
Capecitabine (Xeloda): An Oral Chemotherapy Agent
Herr, R. J. (2010) · Wiley eBooks · doi:10.1002/9780470768594.ch5 · Cited by 3
Cited by
Challenges and Opportunities in Cancer Drug Resistance
Ward, R. A., Fawell, S., Floc’h, N., Flemington, V., McKerrecher, D., & Smith, P. D. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00383 · Cited by 445
Urea Derivatives in Modern Drug Discovery and Medicinal Chemistry
Ghosh, A. K., & Brindisi, M. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01541 · Cited by 401
Carbohydrate-based drugs launched during 2000−2021
Cao, X., Du, X., Jiao, H., An, Q., Chen, R., Fang, P., Wang, J., & Yu, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.020 · Cited by 267
Metadata
- Authors
- Shelton, J., Lu, X., Hollenbaugh, J. A., Cho, J. H., Amblard, F., & Schinazi, R. F.
- Venue
- Chemical Reviews
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-11-23
- Volume
- 116
- Issue
- 23
- Pages
- 14379-14455
- ISSN
- 0009-2665 (ISSN-L)
- 1520-6890
- OpenAlex
- W2549858084
- Cited by
- 409
- References
- 402
- FWCI
- 2.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.